The Russian Ministry of Industry and Trade released a Report on Main Results of the Ministry of Industry and Trade of the Russian Federation in 2017.
Among other things, this document describes the goals and objectives achieved by the Russian pharmaceutical industry in the recent period.
The share of Russian medicines in the pharmaceutical market increases for the fifth consecutive year. In the segment of 7 Nosologies, the share is 39.19% (compared to 10.2% in 2012); in the segment of hepatitis drugs, 31.6% (compared to 5.28% in 2012); the share of drugs for the treatment of oncological diseases is 46.96% (compared to 13.24% in 2012); the share of HIV drugs is 27.24% (compared to 9.92% in 2012); the share of insulin drugs is 11.14% (compared to 6.33% in 2012).
70 Russian competitive medicinal products were registered with the state support since 2009. New molecules, including elpida (HIV), narlaprevir (tuberculosis), and gosogliptin (diabetes mellitus), are being launched in the market.
Total investments in the industry over 2011-2017 reached more than 150 billion rubles. 30 pharmaceutical production sites were opened since 2013. In 2017 alone, 5 pharmaceutical production facilities were launched in St. Petersburg, Moscow, Vladimir, Samara, and Irkutsk regions. Since 2010, 7 plants were built by international pharmaceutical companies, including Novartis, Teva, and Takeda. Other manufacturers, such as Bayer, Janssen, Merck, and Roche, localized their products at the sites of Russian companies.